Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of ITI-1284 in patients experiencing agitation associated with Alzheimers dementia. This multicenter, randomized, double-blind, placebo-controlled Phase 2 study aims to understand how ITI-1284 affects agitation symptoms in this population. Participants receive either ITI-1284 at doses of 10 mg or 20 mg as a rapidly disintegrating tablet taken once daily under the tongue, or a matching placebo tablet taken the same way. The study uses a flexible-dose design and assigns participants randomly to one of the two groups. Treatment is administered daily during the trial. Throughout the study, participants agitation is measured using the Cohen-Mansfield Agitation Inventory total score at Week 12 as the primary outcome. Additional assessments include the Clinical Global Impression-Severity score at Week 12. Participants are monitored for safety and tolerability, and the study lasts until completion around December 2027.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of ITI-1284, a sublingual drug, compared with placebo in treating psychosis associated with Alzheimers disease. This Phase 2, multicenter, randomized, double-blind, placebo-controlled study involves adults aged 55 and older diagnosed with Alzheimers disease and psychosis. The study aims to improve understanding of how ITI-1284 may affect psychotic symptoms in this population. Participants will receive either ITI-1284 tablets at doses of 10 mg or 20 mg or matching placebo tablets, taken once daily by sublingual administration. The study uses a flexible-dose design and follows a parallel-group model with random assignment to the drug or placebo groups. Treatment and assessments are conducted over the study period, with primary measurement of psychosis symptoms at Week 6. Throughout the trial, participants will be monitored regularly for symptom changes using the BEHAVE-AD psychosis subscale and the Clinical Global Impression-Severity score. Cognitive function will be evaluated using the Mini-Mental State Examination. Safety and tolerability will be assessed continuously, and a designated caregiver will support participants. The total study duration extends through to December 2028, with primary outcomes assessed at 6 weeks.